Could a COVID shot boost cancer treatment? new study investigates
NCT ID NCT07341321
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether getting an mRNA COVID-19 vaccine within three months before starting immunotherapy improves outcomes for people with liver cancer. Researchers will review medical records of 200 patients in Austria to compare response rates, survival, and side effects between vaccinated and unvaccinated groups. The goal is to see if the vaccine might help the immune system fight cancer better when combined with checkpoint inhibitors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mRNA COVID-19 vaccine
What this could lead to
If it works, this could suggest that getting a COVID-19 vaccine before starting immune therapy may help liver cancer patients respond better to treatment.
What could go wrong
This is a retrospective study, meaning it looks back at existing data, not a controlled experiment. Results may show correlation, not causation, and could be influenced by other factors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Klinikum Wels-Grieskirchen
Wels, Austria
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Krankenhaus der Barmherzigen Brüder St Veit an der Glan
Sankt Veit an der Glan, Austria
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Medical University of Graz
Graz, 8010, Austria
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ordensklinikum Linz
Linz, Austria
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Hospital St. Pölten
Sankt Pölten, Austria
Contact Phone: •••-•••-•••• Email: •••••@•••••